Medical Coverage Policy Corneal Collagen Crosslinking
Defines coverage for corneal collagen cross-linking (riboflavin + UVA) for progressive keratoconus and corneal ectasia after refractive surgery across Commercial products and notes Medicare (BlueCHiP) stance. Includes clinical indications, definitions of progression, coding guidance, and prior authorization recommendation for commercial products.
No material clinical/coverage changes.
Coverage Summary
This policy defines coverage for corneal collagen cross-linking (CXL: riboflavin + UVA). For Commercial products CXL is covered as medically necessary for progressive keratoconus and corneal ectasia after refractive surgery when the specified progression criteria and prior-conservative-treatment requirements are met. For BlueCHiP for Medicare the policy states that CXL (riboflavin and UVA) is not covered for all indications due to insufficient evidence to determine effects on health outcomes.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.